Home > Healthcare & Medical Devices > Rare Disease Treatment Market

Rare Disease Treatment Market Size By Drug (Biologics, Non-biologics), By Therapeutic Area (Cancer, Blood-related Disorders, Central Nervous System (CNS), Respiratory Disorders, Musculoskeletal Disorders, Cardiovascular Disorders), By Patient (Adult, Pediatric), By Route of Administration (Oral, Injectable), Industry Analysis Report, Regional Outlook, Growth Potential, Application Potential, Competitive Market Share & Forecast, 2023-2032

  • Report ID: GMI3873
  • Published Date: Jan 2023
  • Report Format: PDF

Industry Statistics

Rare Disease Treatment Market size reached over USD 195 billion in 2022 and is anticipated to exhibit more than 8.5% CAGR through 2023-2032, owing to the increasing drug research and approval.
 

Get more details on this report - Request Free Sample PDF
 

Given the growing burden of rare diseases, federal government agencies are emphasizing drug approvals through grant administrations for treatment research. For instance, in 2020, the U.S. FDA approved drugs to treat a disease with bladder dysfunction called neurogenic detrusor overactivity, observed in patients with spinal cord injury and multiple sclerosis. The pharma sector has also been targeting treatment commercialization through growing focus on the novelty of the mechanism of action compared to traditional medications. The rapid introduction of therapeutic molecular medicines will therefore create lucrative growth prospects for rare disease treatment centers worldwide.
 

Despite the growth trajectory, the high cost of rare disease therapies and drugs may assert a negative influence on the industry outlook to a certain extent. As per statistics from IQVIA, in 2020, the average cost for rare disease treatment per patient was estimated at around USD 32,000 per year. Patients with rare diseases also require accessible and adequate health coverage to maintain health for longer periods. These increased costs are mainly due to delayed drug imports and are likely to create roadblocks to rare disease treatment market progress to some extent.
 

Cost-effectiveness and other attributes fuel non-biologic drug adoption for rare disease treatment

Get more details on this report - Request Free Sample PDF
 

Non-biologics drug segment is set to register over 10% CAGR through 2032, on account of the immunogenicity and minimal side effects associated with such products. These drugs are deemed effective for treating certain conditions including APDS (activated phosphoinositide 3-kinase delta syndrome) and Felty Syndrome. These factors, alongside cost-effectiveness and non-complexity in clinical studies, are projected to augment the consumption of non-biologic medications among rare disease patients.
 

Growing burden of CNS disorders to drive development of precision treatments for rare diseases

Rare disease treatment market value from the central nervous system (CNS) segment is expected to surpass USD 38 billion by 2032, given the rising prevalence of disorders that affect nerve cells in the spinal cord and brain, causing loss of muscle control. Based on data from the National Library of Medicine, amyotrophic lateral sclerosis affects around 5 in 100,000 people worldwide. Moreover, the strong focus on the development of precision medicines will further drive the demand for therapies to treat rare diseases.
 

High prevalence of Byler disease in children to boost acceptance of pediatric rare disease therapies

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Market size for rare disease treatment reached over USD 195 billion in 2022 and is anticipated to exhibit more than 8.5% CAGR through 2023-2032, due to the increasing drug research and approval.
Rare disease treatment industry share from the non-biologics drug segment is set to register over 10% CAGR through 2023-2032, on account of their immunogenicity and minimal side effects.
Europe rare disease treatment industry size will exceed USD 115.5 billion by 2032, owing to the rising disease burden and the shifting preference toward early disease diagnosis.
Vertex Pharmaceuticals Incorporated, Biogen, Pfizer Inc., Novartis AG, Merck, Johnson & Johnson, Bayer AG, Amgen Inc., Alexion Pharmaceuticals, and AbbVie Inc. are some of the prominent players in the rare disease treatment business.

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 22
  • Tables & Figures: 352
  • Countries covered: 30
  • Pages: 225
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount